References
1. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1998). Bethesda, MD: National Cancer Institute; 2002. Available at: http://www.seer.cancer.gov. Accessed October 2002.
2. Silverberg E, Boring CC, Squires TS. Cancer Statistics, 1990. CA Cancer J Clin 1990;40:9-26.
3. Ershler WB, Longo DL. Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 1997;89:1489-97.
4. U.S. Bureau of the Census. Current Population Survey, July 2002. Available at: http://www.census.gov. Accessed October 2002.
5. Soldo BJ, Agree EM. America's elderly. 1988: Population Reference Bureau, Inc, Washington, DC.
6. Lash TL, Silliman RA. Prevalence of cancer. J Natl Cancer Inst 1998;90:399-400.
7. Greenfield S, Blanco DM, Slashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. JAMA 1987;257:2766-70.
8. Caplan LS, Wells BL, Haynes S. Breast cancer screening among older racial/ethnic minorities and whites: barriers to early detection. J Gerontol 1992;47 Spec No:101-10.
9. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-10.
10. Brown ML. Economic considerations in breast cancer screening of older women. J Gerontol 1992;47:51-8.
11. Kerlikowske K, Grady D, Barclay J, Sickles EA, Eaton A, Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 1994;271:982-3.
12. Hutchinson GB, Shapiro S. Lead time gained by diagnostic screening for breast cancer. J Natl Cancer Inst 1968;41:665-81.
13. Duffy SW, Chen HH, Tabar L, Day NE. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Stat Med 1995;14:1531-43.
14. Gapstur SM, Dupuis J, Gann P, Collila S, Winchester DP. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer 1996;77:1465-71.
15. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994;86:705-12.
16. Ershler WB, Balducci L. Treatment considerations for older patients with cancer. In Vivo 1994;8:737-44.
17. Lyman GH, Lyman S, Balducci L, et al. Age and the risk of breast cancer recurrence. Cancer Control 1996;3:421-27.
18. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709-17.
19. Russell LB, Siegel JE, Daniels N, Gold MR, Luce BR, Mandelblatt JS. Cost-effectiveness analysis as a guide to resource allocation in health: roles and limitations. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996: 3-24.
20. Teutsch SM, Murray JF. Dissecting cost-effectiveness analysis for preventive interventions: a guide for decision makers. Am J Manage Care 1999;5:301-5.
21. Mandelblatt JS, Fryback DG, Weinstein MC, Russell LB, Gold MR. Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J Gen Intern Med 1997;12:551-8.
22. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991;49:531-7.
23. van der Maas PJ, de Koning HJ, van Ineveld BM, et al. The cost-effectiveness of breast cancer screening. Int J Cancer 1989;43:1055-60.
24. Desch CE, Hillner BE, Smith TJ, Retchin SM. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 1993;11:777-82.
25. Lindfors KK, Rosenquist CJ. The cost-effectiveness of mammographic screening strategies. JAMA 1995;274:881-4.
26. Eddy DM. Screening for breast cancer. Ann Intern Med 1989;111:389-99.
27. Kerlikowske K, Salzmann P, Phillips KA, Cauley JA, Cummings S. Continuing screening mammography in women aged 70 to 79 years. Impact on life expectancy and cost-effectiveness. JAMA 1999;282:2156-63.
28. Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS. The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. Am J Prev Med 2001;20:36-43.
29. Bureau of Labor Statistics, 2000. Available at: http://www.bls.gov. Accessed October 2002.
30. Messecar DC. Mammography screening for older women with and without cognitive impairment. J Gerontol Nurs 2000;26:14-24.
31. Boer R, de Koning HJ, Threlfall A, et al. Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. BMJ 1998;317:376-9.
32. Mandelblatt JS, Wheat ME, Monane M, Moshief R, Hollenberg J, Tang J. Breast cancer screening for elderly women with and without comorbid conditions: a decision analysis model. Ann Intern Med 1992;116:722-30.
33. Boer R, de Koning HJ, van der Maas PJ. A longer breast carcinoma screening interval for women age older than 65 years? Cancer 1999;86:1506-10.
34. Rosenquist CJ, Lindfors KK. Screening Mammography Beginning at Age 40 Years: a Reappraisal of Cost-Effectiveness. Cancer 1998;82:2235-40.
35. United States Preventive Services Task Force. Breast Cancer-Screening: Summary of Recommendations. Available at: http://www.ahrq.gov/clinic/uspstf/uspsbrca.htm. October 2002.
36. Breen N, Wesley MN, Merrill RM, Johnson K. The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. Ethn Dis 2000;9:111-25.
37. Mandelblatt JS, Hadley J, Kerner JF, et al. Patterns of breast carcinoma treatment in older women: patient preferences, and clinical and physician influences. Cancer 2000;89:561-73.
38. Kerner JF, Mandelblatt JS, Silliman RA, et al. Screening mammography and breast cancer treatment patterns in older women. Breast Cancer Res Treat 2001;69:81-91.
39. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast exams. N Engl J Med 1998;338:1089-96.
40. Feurer EJ, Wun LM. How much of the recent rise in breast cancer incidence can be explained by increase in mammography utilization? A dynamic population model approach. Am J Epidemiol 1992;136:1423-36.
41. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129-34.
42. Smith-Bindman R, Kerlikowske K, Gebretsadik T, Newman J. Is screening mammography effective in elderly women? Am J Med 2000;108:112-9.
43. McCarthy EP, Burns RB, Freund KM, Ash AS, Schwartz M, Marwill SL. Mammography use, breast cancer stage at diagnosis, and survival among older women. J Am Geriatr Soc 2000;48:1226-33.
44. Randolph WM, Goodwin JS, Mahnken JD, Freeman JL. Regular mammography use is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis. Ann Intern Med 2002;137:783-90.
45. McPherson CP, Swenson KK, Lee MW. The effects of mammographic detection and comorbidity on the survival of older women with breast cancer. J Am Geriatr Soc 2002;50(6):1061-8.
Return to Contents
Author Affiliations
a. Jeanne Mandelblatt: Department of Oncology, Georgetown University Medical Center, Lombardi Cancer Center, Washington, DC.
b. Somnath Saha, Mark Helfand: Evidence-based Practice Center, Oregon Health & Science University; Section of General Internal Medicine, Portland Veterans Affairs Medical Center; Portland, OR.
c. Steven Teutsch: Merck & Co., Inc., West Point, PA.
d. Tom Hoerger: Evidence-based Practice Center, Research Triangle Institute & University of North Carolina; Center for Economics Research, Research Triangle Institute, Research Triangle Park, NC.
e. Albert L. Siu: Mt. Sinai School of Medicine, Department of Geriatrics, New York, NY.
f. David Atkins: Senior Research Scientist, Agency for Healthcare Research and Quality.
g. Jonathan Klein: Department of Pediatrics, University of Rochester, Rochester, NY.
Return to Contents
Copyright and Source Information
This document is in the public domain within the United States. For information on reprinting, contact Randie Siegel, Director, Division of Printing and Electronic Publishing, Agency for Healthcare Research and Quality, Suite 2000, 540 Gaither Road,
Rockville, MD 20850. Requests for linking or to incorporate content in electronic resources should be sent to: info@ahrq.gov.
Source
This article originally appeared in Ann Intern Med 2003;139(10):835-42.
Return to Contents
Current as of November 2003
Internet Citation:
Mandelblatt J, Saha S, Teutsch S, Hoerger T, Siu AL, Atkins D, Klein J, Helfand M. The Cost-Effectiveness of Screening Mammography Beyond Age 65: A Systematic Review for the U. S. Preventive Services Task Force. Originally in Ann Intern Med 2003;139(10):835-42. November 2003. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/3rduspstf/breastcancer/brcancost.htm
540 Gaither Road Rockville, MD 20850